Use of pretreatment chemicals to enhance efficacy of cytotoxic a

Details Use of pretreatment chemicals to enhance efficacy of cytotoxic a Use of pretreatment chemicals to enhance efficacy of cytotoxic a

1997-08-29

2000-07-11

Cintins, Marianne M.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

9,10-seco- cyclopentanohydrophenanthrene ring system doai

514170, 514653, 514167, 514449, 514110, 514 23, A61K 3159

Patent

active

060873507

ABSTRACT:
The present invention provides a method of killing a cell by first administering to the cell a vitamin D derivative and subsequently administering to the cell a cytotoxic agent. Where the cell is within a tumor, the present invention provides a method of retarding the growth of the tumor by first administering the vitamin D derivative to the tumor and subsequently administering to the tumor the cytotoxic agent.

REFERENCES:
patent: 4973721 (1990-11-01), Ikekawa et al.
patent: 5763429 (1998-06-01), Bishop et al.
patent: 5795882 (1998-08-01), Bishop et al.
Cho et al., Combined Effects of . . . , Cancer Research, vol. 51. p. 284853, 1991.
Nishio et al., Calcitriol increases . . . , The Cancer Journal, vol. 6, p. 97-101, 1993.
Revillion et al., 1,25-dihydroxyvitamin D3 and . . . , Int.J.Oncol. vol. 5(5), p. 1131-6, 1994.
Abe et al., A novel vitamin . . . , Endocrinology, vol. 129(2), p. 832-837, 1991.
Calverley et al., Vitamin D, Antitumor Steroids, p. 193-270, 1992.
Abe, J. et al., Cancer Res., 46, 6313-6321 (1986).
Abe-Hashimoto, J. et al., Cancer Res., 53, 2534-2537 (1993).
Bilezikian, J.P., The New England Journal of Medicine, 326(18), 1196-1203.
Binderup, E. et al., in Vitamin D: Processings of the 8th Workshop on Vitamin D, Paris, France (A. Norman et al., Eds., Walter de Gruyter, Berlin, 1991, p. 192).
Binderup, L. et al., Biochemical Pharmacology, 42(8), 1569-1575 (1991).
Calverley et al., in Antitumor Steroids (Blickenstaff, R.T., Ed., Academic Press, Orlando, 1992, pp. 193-270).
Campbell, M.J. et al., J. Mol. Endocrinol., 19, 15-27 (1997).
Campbell, M.J. et al., Journal of the National Cancer Institute, 89(3), 182-185 (1997).
Cho, Y.L. et al., Cancer Res., 51, 2848-2853 (1991).
Clark, J.W. et al., J. Cancer Res. Clin. Oncol., 118, 190-194 (1992).
Colston, K. et al., Endocrinology, 108(3), 1083-1086 (1981).
Cross, H.S. et al., Arch. Pharmacol., 347, 105-110 (1993).
DeLuca, H., FASEB J., 2, 224-236 (1988).
Dilworth, F.J. et al., Biochemical Pharmacology, 47(6), 987-993 (1994).
Eisman, J. et al., Cancer Res., 47, 21-25 (1987).
Eisman, J.A. et al., Lancet, 2, 1335-1336 (1979).
Elstner, E. et al., Cancer Research, Aug. 1, 1996, pp. 3570-3576.
Frampton, R.J. et al., Cancer Res., 43, 4443-4447 (1983).
Hengst, L. et al., Science, 271, 1861-1864.
Honma, Y. et al., Proc. Natl. Acad. Sci. USA, 80, 201-204 (1983).
Koeffler, H.P. et al., Cancer Treatment Rep., 69, 1399-1407 (1985).
Liu, M. et al., Genes and Devel., 10, 142-153 (1996).
McCollum, E. et al., J. Biol. Chem., 53, 293-312 (1922).
McElwain, M.C. et al., Mol. Cell. Differ., 3, 31-50 (1995).
Mellanby, E. et al., Lancet, 1, 407-412 (1919).
Miller, G.J. et al., Cancer Res., 52, 515-520 (1992).
Minghetti, P.P. et al., FASEB J., 2, 3043-3053 (1988).
Munker, R. et al., Blood, 88(6), 2201-2209.
Munker, R. et al., J. Clin. Invest., 78, 424-430 (1986).
Peleg, S. et al., Journal of Biological Chemistry, 270 (18), 10551-10558 (1995).
Raina, V. et al., Br. J. Cancer, 63, 4673 (1991).
Rigby, W.F. et al., J. Immunol., 135(4), 2279-2286 (1985).
Russell, R.M., JAMA, 273(21), 1699-1700 (1995).
Saunders, D.E. et al., Gynecologic Oncology, 51, 155-159 (1993).
Saunders, D.E. et al., Abstract 1787, Proc. Am. Cancer Res., 34, 300 (1993).
Smith, J.M. et al., Abstract 761, Proc. Am. Assn. Cancer Res., 34, 128 (1993).
Studzinski, G.P. et al., Critical Reviews in Eukaryotic Gene Expression, 3(4), 279-312 (1993).
Tanaka, H. et al., Clinical Orthopaedics and Related Research, 247, 290-296 (1989).
Tsuchiya, H. et al., Journal of Orthopaedic Research, 11(1), 122-130 (1993).
van den Bemd, G.C.M. et al., Proc. Natl. Acad. Sci. USA, 93, 10685-10690 (1996).
Walters, M.R. Endocr. Rev., 13, 719-764 (1992).
Wang, Q.M. et al., Cancer Res., 56, 264-267 (1996).
Waxman, S. et al., Cancer Res., 50, 3878-3887 (1990).
Xu, H. et al., Experimental Cell Research, 209, 367-374 (1993).
Yu, W. et al., Abstract 1771, Proc. Am. Assn. Cancer Res., 36, 298 (1995).
Zhou, J.Y. et al., Blood, 73, 75-82 (1991).
Saunders, D.E. et al., Abstract No. 2641, Proc. Am. Assoc. for Cancer Research, 33, 442 (1992).
Saunders, D.E. et al., Abstract No. 1949, Proc. Am. Assoc. for Cancer Research, 35, 327 (1994).
Abe et al., Endocrinology, 129 (2), 832-837 (1991).
Jimenez et al., Cancer Res., 52 (18), 5123-5125 (1992).
Nishio et al., Cancer Journal, 6 (2), 97-101 (1993).

Affiliated with

Also associated with

Rating

Use of pretreatment chemicals to enhance efficacy of cytotoxic a does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of pretreatment chemicals to enhance efficacy of cytotoxic a, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of pretreatment chemicals to enhance efficacy of cytotoxic a will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-542590